Indian Dermatology Online Journal最新文献

{"title":"Oral and Lip Depigmentation Induced by Bael Leaves and Clove Phytochemicals.","authors":"Prashant B Jadhav","doi":"10.4103/idoj.idoj_661_25","DOIUrl":"10.4103/idoj.idoj_661_25","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"746-748"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Intriguing, Solitary Nodule on the Nose.","authors":"Veena Nandakumar, Karalikkattil T Ashique","doi":"10.4103/idoj.idoj_553_26","DOIUrl":"10.4103/idoj.idoj_553_26","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"769-771"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148827897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Localized Cutaneous Amyloidosis: A Histological and Immunohistochemical Appraisal.","authors":"Nithye Parvathy, Rashmi Joshi, Rajsmita Bhattacharjee, Uma N Saikia, Dipankar De, Debajyoti Chatterjee","doi":"10.4103/idoj.idoj_629_25","DOIUrl":"10.4103/idoj.idoj_629_25","url":null,"abstract":"<p><strong>Background: </strong>Primary localized cutaneous amyloidosis (PLCA) is a rare chronic heterogeneous group of disorders with deposition of abnormally folded beta-pleated protein in the dermo-epidermal junction and dermis. There are three major forms of PLCA, including lichen amyloidosis, macular amyloidosis, nodular amyloidosis, and a rare variant, amyloidosis cutis dyschromica. We aimed to evaluate the role of immunohistochemistry (IHC) in the diagnosis of PLCA.</p><p><strong>Patients and methods: </strong>A retrospective 8-year audit (2017-2024) was performed. All cases of PLCA were subjected to a panel of IHC, including high molecular weight cytokeratin (HMWCK), Kappa and Lambda light chains; and serum amyloid A. The demographic details and clinical features, along with site predilection, were correlated with the pathological subtypes.</p><p><strong>Results: </strong>We included 42 cases of PLCA, among which lichen amyloidosis was the most common subtype (50%), followed by macular amyloidosis, nodular amyloidosis, and amyloidosis cutis dyschromica, with a predilection for the upper back. IHC displayed HMWCK positivity in cases of lichen amyloidosis (14/21, 66.7%), macular amyloidosis (7/11, 63.6%), and amyloidosis cutis dyschromica (2/3, 66.7%). All cases of nodular amyloidosis showed light chain restriction using a combination of IHC and direct immunofluorescence.</p><p><strong>Limitations: </strong>Retrospective nature of the study, relatively small sample size, and not performing IHC for other small molecular weight keratins.</p><p><strong>Conclusion: </strong>The findings in our study confirm that the amyloid in macular amyloidosis, lichen amyloidosis, and amyloidosis cutis dyschromica is derived from epidermal keratinocytes. IHC for HMWCK should be part of diagnostic workup as it can detect very small amount of amyloid deposition, which may be overlooked during routine evaluation. Nodular amyloidosis demonstrates light chain restriction, indicating the need to exclude systemic amyloidosis.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"683-687"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What IDOJ Expects from its Authors in the Evolving Landscape of Use of Artificial Intelligence in Scientific Writing.","authors":"Dipankar De, Hitaishi Mehta","doi":"10.4103/idoj.idoj_951_26","DOIUrl":"10.4103/idoj.idoj_951_26","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"625-626"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perianal Ulcerative Plaque: An Unusual Presentation of Cutaneous Tuberculosis.","authors":"Lipsa Kumari, Vaishnavi Verma, Sudheer Arava, Neetu Bhari","doi":"10.4103/idoj.idoj_298_25","DOIUrl":"10.4103/idoj.idoj_298_25","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"722-724"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scoring Systems in Vitiligo-A Narrative Review.","authors":"Shivani Bansal, Pooja A Mrig, Himani Chawla, Sushma Sushama, Priyanka Karadia","doi":"10.4103/idoj.idoj_1220_25","DOIUrl":"10.4103/idoj.idoj_1220_25","url":null,"abstract":"<p><strong>Abstract: </strong>Vitiligo is an acquired autoimmune disorder with a worldwide prevalence of 0.5-1%. It is characterized by depigmented macules caused by the absence of melanocytes in the epidermis.The aim of the treatment for vitiligo is disease stabilization and repigmentation. Hence, different scores have been developed to assess disease severity and repigmentation in order to infer the therapeutic efficacy of the chosen treatment. Vitiligo is associated with social stigma and has an immense effect on the patients' quality of life. Hence, scores have been developed to assess the impact of the disease. A comprehensive literature search was conducted using keywords such as \"vitiligo,\" \"scoring system,\" \"activity,\" \"extent,\" \"area,\" \"repigmentation,\" \"quality of life,\" \"vitiligo disease burden,\" and \"impact,\" individually or in combination. Databases searched included PubMed, Embase, the Cochrane Library, and ScienceDirect. Articles published up to May 2025 were considered for inclusion. These scores are essential for evaluating vitiligo in medical research and clinical practice. These are needed for assessment, treatment evaluation, and monitoring disease progression. This review article summarizes the scoring systems used in day-to-day practice and research trials. Eleven scores assess the extent of disease and/or repigmentation, while nine monitor disease activity. Seven scores evaluate the impact on patients' or their families' quality of life. Additional research is needed to assess the validity, reliability, and responsiveness of each score.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"627-638"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ulcerated Plaque with Multifocal Necrotizing Lymphadenopathy in a Young Male.","authors":"Apoorva Sharma, Gaurav Prakash, Debajyoti Chatterjee, Dipankar De","doi":"10.4103/idoj.idoj_280_25","DOIUrl":"10.4103/idoj.idoj_280_25","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"734-736"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution of Recalcitrant Extensive Verruca Plana with Pulsed-Dye Laser.","authors":"Aysha Najeeb, Rhea Ahuja, Sujay Khandpur, Neetu Bhari","doi":"10.4103/idoj.idoj_440_25","DOIUrl":"10.4103/idoj.idoj_440_25","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"711-712"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Double Trouble in Porokeratosis: Exploring Coexistent Porokeratosis Ptychotropica and Mibelli in Four Patients.","authors":"Sagnik De, Atul Mohan, Satyendra K Singh","doi":"10.4103/idoj.idoj_228_25","DOIUrl":"10.4103/idoj.idoj_228_25","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"725-727"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146179363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Ixekizumab in Moderate-to-Severe Plaque Psoriasis in the Indian Population: A Pilot Study.","authors":"Teghveer Singh, Shailendra Srivastava, Ruby Venugopal, Reetu Agarwal, Eeshaan Ranjan, Priyanka Gupta","doi":"10.4103/idoj.idoj_1091_25","DOIUrl":"10.4103/idoj.idoj_1091_25","url":null,"abstract":"<p><strong>Background: </strong>India has a significant burden of psoriasis, with an incidence reported between 0.44% and 2.2% among total dermatology patients and a reported prevalence of 4.78% over 5 years. Psoriasis is now recognized as a multisystem disease, and targeted therapies are needed to reduce morbidity. The need for newer biologics exists not only for better disease control but also to treat patients who manifest primary or secondary failure to a previous biologic. Ixekizumab is a newer IL-17 inhibitor that has recently been approved by the Drug Controller General of India for use in patients with psoriasis vulgaris in India.</p><p><strong>Aims and objectives: </strong>To evaluate the effectiveness and safety of ixekizumab in the treatment of patients with plaque psoriasis of Indian origin.</p><p><strong>Patients and methods: </strong>The study was a prospective, single-center, single-arm interventional study approved prospectively by Clinical Trial Registry-India with reg. no. CTRI/2025/02/081205. The induction phase of ixekizumab was used to treat 40 patients with moderate-to-severe plaque psoriasis. The psoriasis area severity index (PASI), body surface area (BSA), and dermatology life quality index (DLQI) were measured at 2, 4, and 12 weeks of therapy. Median values of absolute PASI and BSA were assessed statistically using the Friedman test and Wilcoxon-signed rank test. PASI 75/90/100 responses were measured at 2, 4, and 12 weeks and analyzed using Cochran's Q test and McNemar test. Safety and adverse events, if any, were documented.</p><p><strong>Results: </strong>The median absolute PASI, BSA, and DLQI showed progressive improvement during the study period and these values when compared between baseline and 12 weeks were statistically significant. PASI 75/90/100 at the end of 12 weeks was 100%, 75%, and 20%, respectively. All eleven patients who had primary or secondary failure to a previous biologic showed a comparable response to that achieved by biologic naïve patients. No major adverse events were noted.</p><p><strong>Limitations: </strong>Considering that it is a pilot study which concluded in the induction phase of the treatment, long-term treatment outcomes and adverse events cannot be commented upon.</p><p><strong>Conclusion: </strong>Ixekizumab achieved high PASI targets during the induction phase. The treatment improved the DLQI significantly. It has an excellent safety profile in the Indian population. Its effectiveness in patients with previous biologic failure is comparable to that in biologic naïve patients.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":"648-653"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13588451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}